Literature DB >> 22727143

Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia.

Khaled M Musallam1, Irene Motta, Marta Salvatori, Mirella Fraquelli, Alessia Marcon, Ali T Taher, Maria Domenica Cappellini.   

Abstract

Despite evidence of considerable iron overload in transfusion-independent patients with β-thalassemia intermedia, data on hepatic outcomes remain scarce. We analyzed data from a cohort of 42 β-thalassemia intermedia adults followed for four years (median age 38years), and evaluated the association between longitudinal changes in serum ferritin levels and transient elastography values, a measure of hepatic stiffness predictive of fibrosis. We observed a significant increase in both serum ferritin levels (+81.2 [μg/l]/year) and transient elastography values in non-chelated patients (n=28) (+0.3kPa/year), with two patients worsening their fibrosis stage. Chelated patients (n=14) had a significant decrease in both measures (-42.0 [μg/l]/year and -0.9kPa/year, respectively), with two patients improving their fibrosis stage. There was a strong correlation between the rate of change in serum ferritin level and the rate of change in transient elastography value (R(2): 0.836, p<0.001) noted in both non-chelated and chelated patients. An association between iron overload status and hepatic disease merits further evaluation in this subset of transfusion-independent patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727143     DOI: 10.1016/j.bcmd.2012.06.001

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  14 in total

Review 1.  Management of non-transfusion-dependent thalassemia: a practical guide.

Authors:  Ali T Taher; Maria Domenica Cappellini
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

Review 2.  Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.

Authors:  Matt Shirley; Greg L Plosker
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

Review 3.  Non-transfusion-dependent thalassemias.

Authors:  Khaled M Musallam; Stefano Rivella; Elliott Vichinsky; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

Review 4.  Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.

Authors:  Paolo Ricchi; Maria Marsella
Journal:  Drug Des Devel Ther       Date:  2015-12-16       Impact factor: 4.162

Review 5.  β-Thalassemia Intermedia: A Bird's-Eye View.

Authors:  Anthony Haddad; Paul Tyan; Amr Radwan; Naji Mallat; Ali Taher
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

Review 6.  Novel approach to reactive oxygen species in nontransfusion-dependent thalassemia.

Authors:  Paul I Tyan; Amr H Radwan; Assaad Eid; Anthony G Haddad; David Wehbe; Ali T Taher
Journal:  Biomed Res Int       Date:  2014-07-09       Impact factor: 3.411

Review 7.  Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.

Authors:  Valeria Maria Pinto; Gian Luca Forni
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

Review 8.  Treating iron overload in patients with non-transfusion-dependent thalassemia.

Authors:  Ali T Taher; Vip Viprakasit; Khaled M Musallam; M Domenica Cappellini
Journal:  Am J Hematol       Date:  2013-03-08       Impact factor: 10.047

9.  Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia.

Authors:  João Arezes; Niall Foy; Kirsty McHugh; Doris Quinkert; Susan Benard; Anagha Sawant; Joe N Frost; Andrew E Armitage; Sant-Rayn Pasricha; Pei Jin Lim; May S Tam; Edward Lavallie; Debra D Pittman; Orla Cunningham; Matthew Lambert; John E Murphy; Simon J Draper; Reema Jasuja; Hal Drakesmith
Journal:  Blood       Date:  2020-02-20       Impact factor: 25.476

10.  Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.

Authors:  Ali T Taher; John B Porter; Vip Viprakasit; Antonis Kattamis; Suporn Chuncharunee; Pranee Sutcharitchan; Noppadol Siritanaratkul; Raffaella Origa; Zeynep Karakas; Dany Habr; Zewen Zhu; M Domenica Cappellini
Journal:  Eur J Haematol       Date:  2014-03-25       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.